Global Diabetes Drugs Market Analysis, Growth, Trends & Forecast 2018-2023, With an Expected CAGR of 7% - ResearchAndMarkets.com

August 2, 2018

DUBLIN--(BUSINESS WIRE)--Aug 2, 2018--The “Global Diabetes Drugs Market - Segmented by Drugs and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The global diabetes drugs market is expected to register a CAGR of around 7% during the forecast period of 2018-2023. Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose, either because insulin production is inadequate, or because the body’s cells do not respond properly to insulin, or both.

Diabetes is one of the most malignant diseases of the 21st century. WHO predicts that diabetes would be the seventh most leading cause of death by 2030. Prevalence of diabetes increased from 108 million in 1980 to 422 million in 2014. The rising prevalence of diabetes in the United States is the most influencing factor driving the market for diabetes drugs. 9.3% of the population of the United States, i.e., 29.1 million is diabetic. While 21 million of them have been diagnosed, 8.1 million remain undiagnosed. Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three by 2050.

Drugs for diabetes are rather expensive for a large segment of diabetic patients. While there are only few moderately priced generic drugs available such as Metformin drugs, all the other drugs that are more effective are costly and have fewer side effects.

In 2017, the United States diabetes drugs market held the largest market share in North America due to the presence of high quality healthcare system and increasing prevalence of diabetes in this region.

Companies Mentioned

Abbott Laboratories Johnson & Johnson Merck & Co. Novo Nordisk Eli Lilly and Company AstraZeneca GlaxoSmithKline PLC Bayer AG

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

11. Disclaimer

For more information about this report visit https://www.researchandmarkets.com/research/cb8fdq/global_diabetes?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005501/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/02/2018 09:55 AM/DISC: 08/02/2018 09:55 AM


Update hourly